Young Adults and Low Nicotine Cigarettes

Smoking Clinical Trial

— YLP  

Official title:

Young Adults and Low Nicotine Cigarettes

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03699865
• Other study ID #: 829101
• Secondary ID: 1K07CA218366-01A
• Status: Withdrawn
• Phase: N/A
• Start date: August 1, 2022
• Est. completion date: December 15, 2022

Study information

• Verified date: September 2022
• Source: Abramson Cancer Center of the University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to look at the effects of investigational low nicotine cigarettes on young adult smokers. The investigators are interested in how using these products affects young adults' perceptions and smoking behaviors. This research may help inform the Food and Drug Administration (FDA) how best to regulate tobacco products in the future with the goal of improving public health.

Description:

Investigators will recruit 100 young adult cigarette smokers to a 40-day, laboratory-based protocol. You will provide and smoke your preferred brand cigarettes for an initial 5-day baseline period, then receive your own brand free-of-charge for an additional 5-day period, and then will receive free, investigational low nicotine cigarettes for the remaining study duration (i.e., 30 days total). Low nicotine cigarettes will be provided in three varieties; each variety will be used for a 10-day period, in counterbalanced order. Primary outcomes will include smoking behaviors (daily cigarette consumption and total puff volume), harm perceptions (i.e., beliefs about product safety), and tobacco exposure (i.e., carbon monoxide [CO]). You will complete in-person visits at the Center for Interdisciplinary Research on Nicotine Addiction (CIRNA) every 5 days, for a total of nine in-person visits.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 15, 2022
• Est. primary completion date: December 15, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 29 Years

Eligibility

Inclusion Criteria:

• Study participants will be 100 male and female young adult smokers who:
• Are aged 18-25
• Report smoking = 100 lifetime cigarettes
• Report smoking at least 1 non-menthol, filtered cigarette per day

Exclusion Criteria:

• We will exclude those who:
• Plan to quit smoking in the next month
• Smoke menthol cigarettes > 80% of the time
• Report consuming = 25 alcohol-containing drinks per week
• Report a history or current psychiatric diagnosis or severe medical condition,
• Are color-blind or have another visual impairment (e.g., partial blindness, uncorrected cataract)
• Are pregnant and/or lactating

Additional, general reasons for exclusion include:

• Significant non-compliance with protocol and/or study design as determined by the Principal Investigator and/or Study Physician. Subjects may be deemed ineligible at any point throughout the study.
• Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and/or the study design as determined by the Principal Investigator and/or Study Physician.
• Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator and/or Study Physician. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.

Related Conditions & MeSH terms

• Smoking

Intervention

Other:
• Nicotine content
Study-supplied cigarettes will contain either intermediate or very low nicotine content

Locations

Country	Name	City	State
United States	Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Abramson Cancer Center of the University of Pennsylvania	National Cancer Institute (NCI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Daily cigarette consumption	Daily cigarette consumption will be assessed primarily by participant self-report and secondarily through collection of spent filters for all cigarettes smoked during the 35-day study period, and will be averaged across baseline and pack color periods.	Days 0 through 40
Secondary	Total puff volume	Total puff volume (total smoke inhaled per cigarette) will be collected twice during laboratory visits using a handheld, portable, electronic topography device. Assessments will be averaged across study periods.	Days 0, 5, 10, 15, 20, 25, 30, 35, and 40
Secondary	Risk perceptions	Perceptions of risks of using study cigarettes will be assessed at the end of own brand and pack color periods using individual items and a summary score from an 8-item, 5-point Likert scale (1 = "definitely untrue", 5 = "definitely true") stating: "Compared to your own cigarettes, the cigarettes you are currently smoking…": a) "are lower in nicotine", b) "are lower in tar", c) "are less addictive", d) "are less likely to cause cancer", e) "have fewer chemicals", f) "are healthier", g) "make smoking safer", h) "help people quit smoking."	Days 10, 20, 30, and 40
Secondary	Harm exposure	Harm exposure will be approximated by changes in expired air carbon monoxide (CO), a commonly used biochemical measure of tobacco smoke exposure that is sensitive to changes in puffing behavior. We will assess CO at the onset of each visit to represent daily exposure, as well as before and after each cigarette smoked during laboratory visits. The change in CO values resulting from smoking a cigarette will estimates smoke exposure due to smoking an individual cigarette.	Days 0, 5, 10, 15, 20, 25, 30, 35, and 40